Results 161 to 170 of about 5,953 (211)

Site-Specific PEGylation of Therapeutic Proteins

open access: yesInternational Journal of Molecular Sciences, 2015
The use of proteins as therapeutics has a long history and is becoming ever more common in modern medicine. While the number of protein-based drugs is growing every year, significant problems still remain with their use.
Mark D Distefano, Jonathan K Dozier
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Pegylated interferons

Clinics in Liver Disease, 2003
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire   +2 more sources

Interaction Between PEG Lipid and DSPE/DSPC Phospholipids: An Insight of PEGylation Degree and Kinetics of De-PEGylation

open access: yesColloids and Surfaces B: Biointerfaces, 2017
The degree to which liposomes are PEGylated is the feature, which most influences the length of the presence of stealth liposomes in the bloodstream.
Felisa Cilurzo   +2 more
exaly   +2 more sources

Purification of PEGylated Proteins, with the Example of PEGylated Lysozyme and PEGylated scFv

2014
PEGylation is a common and highly accepted possibility for half-life prolongation of proteins by increasing the hydrodynamic size. The chromatographic purification of PEGylated protein, using PEG (poly-ethylene glycol) of different PEG chain lengths, with the example of lysozyme and a scFv, is described in detail here, and helpful suggestions for the ...
Anna, Moosmann   +2 more
openaire   +2 more sources

PEGylation of Therapeutic Proteins [PDF]

open access: yesBiotechnology Journal, 2010
Abstract Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post‐production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins. Applicability and safety of this technology have been proven by use
Jevsevar, Simona   +2 more
exaly   +4 more sources

Effect of Pegylation on Pharmaceuticals

Nature Reviews Drug Discovery, 2003
Protein and peptide drugs hold great promise as therapeutic agents. However, many are degraded by proteolytic enzymes, can be rapidly cleared by the kidneys, generate neutralizing antibodies and have a short circulating half-life. Pegylation, the process by which polyethylene glycol chains are attached to protein and peptide drugs, can overcome these ...
J Milton Harris
exaly   +3 more sources

Process for Protein PEGylation

Journal of Controlled Release, 2014
PEGylation is a versatile drug delivery technique that presents a particularly wide range of conjugation chemistry and polymer structure. The conjugated protein can be tuned to specifically meet the needs of the desired application. In the area of drug delivery this typically means to increase the persistency in the human body without affecting the ...
Massimo Morbidelli, David Pfister
exaly   +4 more sources

Emerging PEGylated drugs

Expert Opinion on Emerging Drugs, 2009
PEGylation is a pharmaceutical technology that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunological profiles, and thus, enhance its therapeutic effect. Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small organic ...
Jung Seok, Kang   +2 more
openaire   +2 more sources

Smart PEGylation of Trypsin

Biomacromolecules, 2010
Thermoresponsive oligo(ethylene glycol)-based copolymers were investigated for trypsin conjugation. These copolymers have been synthesized by atom transfer radical polymerization of 2-(2-methoxyethoxy)ethyl methacrylate (MEO(2)MA) with oligo(ethylene glycol) methyl ether methacrylate (OEGMA(475), M(n) = 475 g.mol(-1)) at 60 degrees C in the presence of
Zarafshani, Z., Obata, T., Lutz, J.
openaire   +3 more sources

Pegylation

Clinical Pharmacokinetics, 2001
The use of liposomal carriers and the modification of therapeutic molecules through the attachment of poly(ethylene glycol) [PEG] moieties ('pegylation') are the most common approaches for enhancing the delivery of parenteral agents. Although 'classical' liposomes (i.e.
J M, Harris, N E, Martin, M, Modi
openaire   +2 more sources

Home - About - Disclaimer - Privacy